GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cibus Inc (NAS:CBUS) » Definitions » Financial Strength

Cibus (CBUS) Financial Strength : 3 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Cibus Financial Strength?

Cibus has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Cibus Inc displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Cibus did not have earnings to cover the interest expense. Cibus's debt to revenue ratio for the quarter that ended in Mar. 2024 was 10.49. As of today, Cibus's Altman Z-Score is -2.13.


Competitive Comparison of Cibus's Financial Strength

For the Biotechnology subindustry, Cibus's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cibus's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cibus's Financial Strength distribution charts can be found below:

* The bar in red indicates where Cibus's Financial Strength falls into.



Cibus Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Cibus's Interest Expense for the months ended in Mar. 2024 was $-8.33 Mil. Its Operating Income for the months ended in Mar. 2024 was $-18.45 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $16.21 Mil.

Cibus's Interest Coverage for the quarter that ended in Mar. 2024 is

Cibus did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Cibus's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(6.663 + 16.209) / 2.18
=10.49

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Cibus has a Z-score of -2.13, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -2.13 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cibus  (NAS:CBUS) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Cibus has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Cibus Financial Strength Related Terms

Thank you for viewing the detailed overview of Cibus's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Cibus (CBUS) Business Description

Traded in Other Exchanges
N/A
Address
6455 Nancy Ridge Drive, San Diego, CA, USA, 92121
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies.
Executives
Rory B Riggs director, officer: Chief Executive Officer 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Collins James C. Jr. director 1007 MARKET STREET, D-9058, WILMINGTON DE 19898
Jonathan Finn 10 percent owner C/O VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Gerhard Prante director SCHONE AUSSICHT 5, HOFHEIM A. TS 2M 65719
Mark Terrence Finn director VANTAGE CONSULTING GROUP, INC., 3500 PACIFIC AVENUE, VIRGINIA BEACH VA 23451
Jean-pierre Jules Lehmann director 21 ALPINASTRASSE, CH 3780, GSTAAD V8 3780
Keith Allen Walker director 13315 ROXTON CIRCLE, SAN DIEGO CA 92130
Wade Hampton King officer: Chief Financial Officer 750 MEADOWOOD DRIVE, ASPEN CO 81611
Gocal Gregory Francis William officer: See Remarks 13737 BASSMORE DR., SAN DIEGO CA 92129
Peter Beetham director, officer: See Remarks 6455 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Yves J Ribeill director C/O CALYXT, INC., 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Michael A. Carr director, officer: President and CEO 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
William Koschak officer: Chief Financial Officer 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113
Sarah Reiter officer: Chief Business Officer 202 COUSTEAU PLACE, DAVIS CA 95618
Daniel F Voytas officer: Chief Science Officer 2800 MOUNT RIDGE ROAD, ROSEVILLE MN 55113